Asked by: John Glen (Conservative - Salisbury)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what plans he has to procure extended half-life blood clotting factor products for use in the NHS.
Answered by George Freeman
The Department plans to tender for extended half-life Clotting Factor VIII and Factor IX for use in the National Health Service once the products are granted European Union licences and are commercially available.
NHS England has made no decision at this time to whether it will develop a clinical commissioning policy for extended half-life productsbut, through the Clinical Reference Group and discussion with the Department’s Commercial Medicines Unit, will continue to review commissioning of these extended half-life products in the future.
Asked by: John Glen (Conservative - Salisbury)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, if NHS England will develop a clinical commissioning policy on the use of extended half-life blood clotting factor products in people with haemophilia.
Answered by George Freeman
The Department plans to tender for extended half-life Clotting Factor VIII and Factor IX for use in the National Health Service once the products are granted European Union licences and are commercially available.
NHS England has made no decision at this time to whether it will develop a clinical commissioning policy for extended half-life productsbut, through the Clinical Reference Group and discussion with the Department’s Commercial Medicines Unit, will continue to review commissioning of these extended half-life products in the future.
Asked by: John Glen (Conservative - Salisbury)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, pursuant to the Answer of 20 June 2015 to Question 3515, what assessment he has made of the affordability to the NHS of providing screening tests for (a) sickle cell disease, (b) cystic fibrosis, (c) congenital hypothyroidism, (d) phenylketonuria, (e) medium-chain acyl-CoA dehydrogenase deficiency, (f) maple syrup urine disease, (g) isovaleric acidaemia, (h) glutaric aciduria type 1 and (i) homocystinuria (pyridoxine unresponsive); what suppliers are used by the NHS to provide each such test; and if he will make a statement.
Answered by Ben Gummer
The NHS Newborn Bloodspot Screening Programme is directly commissioned by NHS England as part of the Section 7A agreement of the National Health Service Act (2006), as amended by the Health and Social Care Act (2012). It sets out the arrangements under which the Secretary of State for Health delegates to NHS England the responsibility for certain elements of Public Health functions. The affordability of the NHS Newborn Bloodspot Screening Programme is discussed with NHS England as part of the Section 7A agreement.
Information on suppliers used by the NHS is not held centrally.
Asked by: John Glen (Conservative - Salisbury)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, pursuant to the Answer of 20 June 2015 to Question 3515, what evidence on costs the NHS considers before deciding to offer screening for genetic conditions; and if he will make a statement.
Answered by Jane Ellison
The UK National Screening Committee is the national advisory body, which advises Ministers and the National Health Service on all aspects of screening. It makes recommendations on which screening programmes should or should not be introduced based on robust analysis against a set of internationally recognised criteria. Screening should only be introduced where there is evidence that it will be both clinically and cost effective and do more good than harm. The economic evidence supporting the January 2015 expansion of the Newborn Blood Spot Screening Programme to include four new genetic conditions can be found at the following link:
http://www.screening.nhs.uk/policydb_download.php?doc=398
Asked by: John Glen (Conservative - Salisbury)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what the annual cost to the NHS is of providing screening for (a) sickle cell disease, (b) cystic fibrosis, (c) congenital hypothyroidism, (d) phenylketonuria, (e) medium-chain acyl-CoA dehydrogenase deficiency, (f) maple syrup urine disease, (g) isovaleric acidaemia, (h) glutaric aciduria type 1, and (i) homocystinuria (pyridoxine unresponsive) (i) in total and (ii) on average per each test delivered; and how many such tests were undertaken in the latest year for which figures are available.
Answered by Jane Ellison
Data on the annual cost to the National Health Service of providing screening for sickle cell disease (SCD), cystic fibrosis (CF), congenital hypothyroidism (CHT), phenylketonuria (PKU), medium-chain acyl-CoA dehydrogenase deficiency (MCADD), maple syrup urine disease (MSUD), isovaleric acidaemia (IVA), glutaric aciduria type 1 (GA1) and homocystinuria (pyridoxine unresponsive)(HCU) are not held centrally.
From Public Health England data, the following number of tests were undertaken in England in 2014/15:
| Number tested for PKU | Number of babies tested for CHT | Number of babies tested for CF | Number of babies tested for MCADD | Number of babies tested for SCD | |
England | 673,328 | 673,233 | 671,120 | 672,107 | 668,117 | |
|
|
|
|
|
|
No data is available for MSUD, IVA, GA1A and HCU as screening was not routinely offered until January 2015.
Asked by: John Glen (Conservative - Salisbury)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what the (a) names and (b) positions are of all members of NHS England's (i) Clinical Priorities Advisory Group, (ii) Specialised Commissioning Oversight Group and (iii) Specialised Commissioning Committee.
Answered by George Freeman
A list of the names and positons of all members of NHS England’s Clinical Priorities Advisory Group, Specialised Commissioning Oversight Group and Specialised Commissioning Committee has been attached to this answer.